Explore
Validate
Learn20032-1-AP
antibody from Proteintech Group
Targeting: NCOA3
ACTR, AIB1, bHLHe42, CAGH16, KAT13B, p/CIP, RAC3, SRC-3, SRC3, TNRC16, TRAM-1
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 20032-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#20032-1-AP, RRID:AB_10666164
- Product name
- SRC3/NCOA3 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated SRC3/NCOA3 antibody (Cat. #20032-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: FC, IF, IHC, WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Evaluation of the diagnostic utility of NCOA3, Maspin and VHL protein expression in pancreatic ductal adenocarcinoma: An immunohistochemical study.
Pathological discrimination between luteinized thecoma associated with sclerosing peritonitis and thecoma.
Elevated SRC3 expression predicts pemetrexed resistance in lung adenocarcinoma.
A potential target for liver cancer management, lysophosphatidic acid receptor 6 (LPAR6), is transcriptionally up-regulated by the NCOA3 coactivator.
Elkady N, Elgendy W, Badr MT, Aiad H, Samara M, Badr NM
Annals of diagnostic pathology 2024 Dec;73:152356
Annals of diagnostic pathology 2024 Dec;73:152356
Pathological discrimination between luteinized thecoma associated with sclerosing peritonitis and thecoma.
Liu J, Wei J, Yang Y, Wei J
Medicine 2023 Jun 9;102(23):e33911
Medicine 2023 Jun 9;102(23):e33911
Elevated SRC3 expression predicts pemetrexed resistance in lung adenocarcinoma.
Chen Y, Sun Y, Zhao W, Ma Y, Yan Z, Nie X
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 May;125:109958
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 May;125:109958
A potential target for liver cancer management, lysophosphatidic acid receptor 6 (LPAR6), is transcriptionally up-regulated by the NCOA3 coactivator.
Zheng X, Jia Y, Qiu L, Zeng X, Xu L, Wei M, Huang C, Liu C, Chen L, Han J
The Journal of biological chemistry 2020 Feb 7;295(6):1474-1488
The Journal of biological chemistry 2020 Feb 7;295(6):1474-1488
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HeLa cells were subjected to SDS PAGE followed by western blot with 20032-1-AP(NCOA3 antibody) at dilution of 1:300
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of HepG2 cells, using NCOA3 antibody 20032-1-AP at 1:25 dilution and Rhodamine-labeled goat anti-rabbit IgG (red).
- Sample type
- cell line
